Overview

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Alemtuzumab
Busulfan
Cyclophosphamide